X-linked Hypophosphatemia (XLH): A Comprehensive Guide

Overview

X-linked hypophosphatemia (XLH) is a rare, inherited disorder that affects the body's ability to regulate phosphate, an essential mineral for bone health. It is the most common form of hereditary rickets, a condition that causes softening and weakening of the bones.

Who It Affects

XLH affects both children and adults. It is an X-linked dominant condition, meaning the gene mutation occurs on the X chromosome. This has important implications for inheritance:

• Females (who have two X chromosomes) are more commonly affected and often experience milder symptoms.
• Males (who have one X and one Y chromosome) typically have more severe symptoms if they inherit the mutated gene.

Prevalence

XLH is rare, with an estimated prevalence of 1 in 20,000 to 1 in 25,000 individuals worldwide (NIH). It affects all ethnic groups equally. Due to its genetic nature, XLH is present from birth, though symptoms may not appear until later in childhood or adulthood.

Symptoms

Symptoms of XLH vary depending on age and severity but primarily affect the bones, teeth, and muscles. Early diagnosis and treatment can help manage symptoms and improve quality of life.

Symptoms in Children

• Bowed or bent legs (often the first noticeable sign, appearing when the child starts walking).
• Short stature or slower-than-average growth.
• Bone pain, particularly in the legs, knees, or ankles.
• Delayed walking or difficulty walking due to bone deformities.
• Dental abnormalities, such as delayed tooth eruption, abscesses, or poor enamel formation.
• Rickets: Softening of the bones, which can lead to fractures or deformities like a curved spine (scoliosis) or knock-knees.

Symptoms in Adults

Adults with XLH may experience:

• Bone pain, especially in the hips, knees, or ankles.
• Osteomalacia (softening of the bones), leading to fractures or stress injuries.
• Joint pain or stiffness, often due to arthritis or bone deformities.
• Dental problems, including frequent abscesses, tooth decay, or loss of teeth.
• Hearing loss (in some cases, due to abnormal bone growth in the ear).
• Enthesopathy: Pain or stiffness where tendons or ligaments attach to bones (e.g., heels, elbows).

Other Possible Symptoms

• Muscle weakness or fatigue.
• Headaches (rarely, due to calcium deposits in the brain).
• High levels of alkaline phosphatase in blood tests (a marker of bone disease).

Causes and Risk Factors

Causes

XLH is caused by mutations in the PHEX gene (phosphate-regulating endopeptidase homolog, X-linked), located on the X chromosome. This gene plays a critical role in regulating phosphate levels in the body by controlling the production of fibroblast growth factor 23 (FGF23), a hormone that reduces phosphate reabsorption in the kidneys.

In XLH, the PHEX gene mutation leads to excess FGF23, which causes:

• Increased loss of phosphate through the urine (hypophosphatemia).
• Reduced activation of vitamin D in the kidneys, leading to low levels of active vitamin D (calcitriol).

Together, these changes impair bone mineralization, leading to soft, weak bones.

Risk Factors

The primary risk factor for XLH is having a family history of the condition. Since it is X-linked dominant:

• Affected mothers have a 50% chance of passing the mutation to each of their children (sons or daughters).
• Affected fathers will pass the mutation to all their daughters but none of their sons (since sons inherit the Y chromosome from their father).
• In rare cases, XLH can occur due to a spontaneous (de novo) mutation in the PHEX gene, with no family history.

Diagnosis

Diagnosing XLH involves a combination of clinical evaluation, blood tests, imaging, and genetic testing. Early diagnosis is crucial for preventing complications like bone deformities or stunted growth.

Blood Tests

Key blood tests include:

• Serum phosphate: Consistently low levels are a hallmark of XLH.
• Alkaline phosphatase (ALP): Often elevated due to increased bone turnover.
• FGF23: High levels support the diagnosis (though this test is not always available).
• Vitamin D (25-hydroxyvitamin D): May be normal or low, but calcitriol (1,25-dihydroxyvitamin D) is typically low or inappropriately normal.
• Calcium: Usually normal (unlike other forms of rickets).
• Parathyroid hormone (PTH): Typically normal or slightly elevated.

Urinalysis

• Phosphate excretion: Increased loss of phosphate in the urine.
• Calcium excretion: Often normal or low.

Imaging

• X-rays: May show rickets (in children), osteomalacia (in adults), bowed legs, or other bone deformities.
• Dual-energy X-ray absorptiometry (DEXA): Measures bone mineral density, though results may be misleading in XLH due to abnormal bone mineralization.

Genetic Testing

Genetic testing for PHEX gene mutations can confirm the diagnosis, especially in families with a history of XLH. This is particularly useful for:

• Prenatal diagnosis (if there is a known family history).
• Identifying carriers in family members.

Differential Diagnosis

XLH must be distinguished from other causes of rickets or hypophosphatemia, such as:

• Nutritional rickets (due to vitamin D or calcium deficiency).
• Tumor-induced osteomalacia (TIO).
• Autosomal dominant hypophosphatemic rickets (ADHR).
• Hereditary hypophosphatemic rickets with hypercalciuria (HHRH).

Treatment Options

While there is no cure for XLH, treatment aims to correct phosphate and vitamin D deficiencies, improve bone health, and manage symptoms. Treatment is typically lifelong and requires regular monitoring.

Medications

• Phosphate supplements: Oral phosphate (e.g., potassium phosphate or sodium phosphate) is given multiple times a day to maintain normal phosphate levels. Side effects may include diarrhea or stomach upset.
• Active vitamin D analogs: Such as calcitriol or alfacalcidol, these help the body absorb phosphate from the gut and improve bone mineralization. They require careful dosing to avoid high calcium levels (hypercalcemia).

Newer Treatments

• Burosumab (Crysvita): A monoclonal antibody approved by the FDA in 2018 for XLH in children and adults. It works by blocking excess FGF23, thereby increasing phosphate reabsorption in the kidneys. Studies show it improves bone mineralization, growth, and mobility (FDA).

Surgical Interventions

In severe cases, surgery may be needed to correct bone deformities, such as:

• Osteotomies (bone straightening or realignment).
• Joint replacements (e.g., hip or knee) in adults with severe arthritis.
• Dental surgeries to address abscesses or misaligned teeth.

Lifestyle and Supportive Care

• Physical therapy: Helps improve mobility, strength, and reduce pain.
• Orthopedic supports: Braces or shoe inserts may help with bone deformities.
• Pain management: Over-the-counter pain relievers (e.g., acetaminophen or NSAIDs) or prescription medications for chronic pain.
• Dental care: Regular check-ups, fluoride treatments, and prompt treatment of abscesses.
• Nutrition: A balanced diet rich in calcium and vitamin D, though supplements should only be taken under medical supervision.

Living with X-linked Hypophosphatemia

Managing XLH requires a multidisciplinary approach, involving endocrinologists, orthopedists, dentists, and physical therapists. Here are some tips for daily management:

For Children

• Adherence to medication: Phosphate and vitamin D must be taken as prescribed, often 4-5 times daily.
• Regular follow-ups: Monitor growth, bone health, and blood levels every 3-6 months.
• Encourage physical activity: Weight-bearing exercises (e.g., walking, swimming) help strengthen bones.
• Support at school: Work with teachers to accommodate physical limitations or pain.

For Adults

• Medication management: Continue phosphate and vitamin D supplements or burosumab as prescribed.
• Bone health monitoring: Regular DEXA scans or X-rays to check for fractures or osteomalacia.
• Pain management strategies: Heat therapy, gentle stretching, or assistive devices (e.g., canes).
• Dental hygiene: Use fluoride toothpaste, avoid sugary foods, and see a dentist every 6 months.
• Mental health support: Chronic pain or mobility issues can lead to anxiety or depression. Counseling or support groups (e.g., XLH Network) can help.

Practical Tips

• Keep a symptom journal to track pain, mobility, or side effects from medications.
• Use reminder apps for medication schedules.
• Wear supportive footwear to reduce joint stress.
• Avoid high-impact sports that may increase fracture risk.

Prevention

Since XLH is a genetic disorder, it cannot be prevented. However, the following steps can help reduce complications and improve outcomes:

Genetic Counseling

• Families with a history of XLH should seek genetic counseling to understand inheritance risks.
• Prenatal testing or preimplantation genetic diagnosis (PGD) may be options for couples at risk.

Early Diagnosis

• Newborns with a family history of XLH should be screened early with blood tests.
• Children with bowed legs, slow growth, or dental issues should be evaluated for XLH.

Lifestyle Measures

• Avoid excessive caffeine or alcohol, which can worsen bone health.
• Maintain a healthy weight to reduce stress on bones and joints.
• Ensure adequate calcium intake through diet (e.g., dairy, leafy greens) but avoid supplements unless prescribed.

Complications

Without proper treatment, XLH can lead to serious, lifelong complications:

Skeletal Complications

• Bone deformities: Permanent bowing of the legs, knock-knees, or spinal curvature (scoliosis).
• Fractures: Increased risk due to weak bones.
• Osteoarthritis: Early-onset joint degeneration due to abnormal bone shape or stress.
• Short stature: Adults with XLH are often shorter than average due to impaired growth in childhood.

Dental Complications

• Tooth abscesses: Recurrent infections due to poor enamel and dentin formation.
• Early tooth loss: Due to severe decay or abscesses.
• Malocclusion: Misaligned teeth requiring orthodontic treatment.

Other Complications

• Hearing loss: Due to abnormal bone growth in the ear (ossification).
• Enthesopathy: Chronic pain at tendon/ligament insertions (e.g., Achilles tendon, elbows).
• Hyperparathyroidism: Overactivity of the parathyroid glands due to chronic phosphate supplementation.
• Nephrocalcinosis: Calcium deposits in the kidneys (rare, but possible with long-term treatment).

When to Seek Emergency Care

Resources and Support

For more information and support, consider these resources:

• XLH Network: A patient advocacy group offering education and community support.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
• Mayo Clinic: Search for XLH or rickets for detailed medical information.
• National Organization for Rare Disorders (NORD).

References:

• National Institutes of Health. (2020). X-Linked Hypophosphatemia. Genes and Disease.
• U.S. Food and Drug Administration. (2018). FDA Approves First Therapy for XLH.
• Mayo Clinic. (2021). Rickets.
• Cleveland Clinic. (2020). X-Linked Hypophosphatemia (XLH).